

# International Journal for Biotechnology and Molecular Biology Research

Volume 7 Number 4, October 2016

ISSN 2141-2154



## ABOUT IJBMBR

The **International Journal for Biotechnology and Molecular Biology Research (IJBMBR)** (ISSN 2141-2154) is published Monthly (one volume per year) by Academic Journals.

**International Journal for Biotechnology and Molecular Biology Research (IJBMBR)** provides rapid publication (monthly) of articles in all areas of the subject such as Green energy from chemicals and bio-wastes, Studies in the graft copolymerization of acrylonitrile onto cassava starch by ceric ion induced initiation, Antimutagenic activity of aqueous extract of Momordica charantia, Ethnomedicinal plants and other natural products with anti-HIV active compounds and their putative modes of action etc.

The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles published in IJBMBR are peer-reviewed.

### Contact Us

**Editorial Office:** [ijbmb@academicjournals.org](mailto:ijbmb@academicjournals.org)

**Help Desk:** [helpdesk@academicjournals.org](mailto:helpdesk@academicjournals.org)

**Website:** <http://academicjournals.org/IJBMBR>

**Submit manuscript online** <http://ms.academicjournals.me/>

## Editors

**Prof Atagana, Harrison**

*Institute for Science and Technology Education  
University of South Africa*

**Prof. UC Banerjee**

*Department of Pharmaceutical Technology  
(Biotechnology)  
National Institute of Pharmaceutical Education and  
Research  
Punjab, INDIA*

**Dr. Y. Omid**

*Faculty of Pharmacy,  
Research Center for Pharmaceutical Nanotechnology,  
School of Advanced Biomedical Sciences,  
Tabriz University of Medical Sciences,  
Tabriz, Iran.*

**Prof. Mohamed E. Wagih**

*University of New Brunswick (UNB-SJ),  
Saint John College, NB,  
E2L 4L5, Canada*

**Dr. Sripada M. Udupa**

*ICARDA-INRA Cooperative Research Project,  
International Center for Agricultural Research in the  
Dry Areas(ICARDA), B.P. 6299,  
Rabat Instituts, Rabat, Morocco*

**Dr. Amjad Masood Husaini**

*Sher-e-Kashmir University of Agricultural Sciences &  
Technology  
Bohlochipora, Dr. Ali Jan Road,  
Nowshera, Srinagar, J&K-190011, India*

**Dr. Om Prakash Gupta**

*Directorate of Wheat Research (ICAR)  
Post Box-158, A  
grasain Marg, Karnal-132001,  
Haryana, India*

## Editorial Board

**Dr. Amro Hanora**

*Suez Canal University, Department of Microbiology  
and Immunology,  
Faculty of Pharmacy, Suez Canal University,  
Box 41522 Ismailia, Egypt*

**Dr. C. Rajasekaran**

*VIT University  
School of Bio-Sciences & Technology (SBST)*

**Dr. Yasar Karadag**

*Gaziosmanpasa University  
Faculty of Agriculture,  
Department of Field Crops, Tokat-Turkey*

**Dr. Ahmet Tutus**

*KSU (Kahramanmaras Sutcu Imam University)  
Faculty of Forestry,  
Department of Forest Industrial Engineering,  
Kahramanmaras 46100 Turkey*

**Dr. Vinod Joshi**

*Desert Medicine Research Centre,  
Indian Council of Medical Research  
New Pali Road, Jodhpur, India*

**Dr. Eshrat Gharaei Fathabad**

*K.M.18 Khazarabad road,  
Sari, Mazandaran, Iran*

**Dr. Shashideep Singhal**

*121 Dekalb Ave, Brooklyn,  
NY 11201, New York, USA*

**Dr Masayoshi Yamaguchi**

*101 Woodruff Circle, 1305 WMRB,  
Atlanta, Georgia 30322-0001, USA*

**Dr. Okonko Iheanyi Omezuruike**

*Department of Virology,  
Faculty of Basic Medical Sciences,  
College of Medicine,  
University College Hospital,  
Ibadan, Nigeria*

**Dr. S. M. Shahid**

*University of Karachi,  
Karachi-75270, Pakistan*

**Prof. Reda Helmy Sammour**

*Botany Department,  
Faculty of Science,  
Tanta University,  
Tanta, Egypt*

**Dr. Premendra D. Dwivedi**

*Food Toxicology Division,  
Room No 303,  
P.O. Box 80,  
M. G. Road, Lucknow-226001, UP, India*

**Dr. Amro Hanora**

*Microbiology and Immunology department,  
Faculty of Pharmacy,  
Suez Canal University,  
Box 41522 Ismailia, Egypt*

**Dr. Tamilnadu**

*1501 N. Campbell Ave  
Tucson, AZ 85724 India*

**Dr. Yadollah Omid**

*Faculty of Pharmacy,  
Tabriz University of Medical Sciences,  
Daneshghah St., Tabriz, Iran*

**Dr. Mohsen Selim Asker**

*National Research Centre, Dokki, Cairo,  
Egypt*

**Dr. Fanuel Lampiao**

*P.O.Box 360, Blantyre, Malawi*

**Prof. Mohamed E. Wagih**

*Saint John, NB, E2L 4L5, Canada*

**Dr. Santosh Kumar Singh**

*Centre of Experimental Medicine and Surgery,  
Institute of Medical Sciences,  
Banaras Hindu University, Varanasi-221005, India*

**Dr. Zhanhuan Shang**

*No.768, Jiayuguan West Road,  
Lanzhou City, Gansu Province, China*

**Dr. Worlanyo Eric Gato**

*Southern Illinois University – Carbondale,  
1245 Lincoln Dr, 144 Neckers, Carbondale IL 62901*

**Dr. Chun Chen**

*College of Life Sciences,  
China Jiliang University  
Xueyuan Street, Xiasha, Hangzhou,  
Zhejiang Province, PR China*

**Dr. Efthimios J.Karadimas**

*LGI, Leeds NHS Trust 10th Timoleonos Vassou str,  
11521, Athens Greece*

**Dr. Samuel Toba Anjorin**

*University of Abuja, Abuja, Nigeria*

**Dr. Rupali Agnihotri**

*Department of Periodontics,  
Manipal college of Dental Sciences,  
Manipal,576104. Karnataka. India*

**Dr. Mahbuba Begum**

*Tuber Crops Research Centre,  
Joydebpur, Gajipur-1701, Bangladesh*

**Prof. S. Mohan Karuppaiyl**

*School of Life Sciences  
Srtm University  
Nanded. MS. India*

**Dr. Neveen Helmy Aboelsoud**

*Complementary Medicine Researches and Application  
Department  
National Research Center, Cairo  
Egypt.*

**Dr. D.E. Chandrashekar Rao**

*National Research Council,  
Plant Biotechnology Institute  
Canada*

**Dr. Nikolaos Papanas**

*Democritus University of Thrace  
G. Kondyli 22, Alexandroupolis, Greece*

**Dr. Sivakumar Swaminathan**

*Iowa State University  
USA*

**Dr. El Sayed Hussein El Sayed Ziedan**

*National Research Centre,  
Plant Pathology Department  
Tahrir St.,Dokki Cairo,  
Egypt*

**Dr. Chethan Kumar M**

*Post Graduate Departments of Bio-technology and Biochemistry,  
Ooty Road, Mysore - 570 025,  
Karnataka,  
India*

**Dr. M. Sattari**

*Rice Research Ins. of Iran  
Iran*

**Dr. Zaved Ahmed Khan**

*VIT University  
India*

**Dr. Subbiah Poopathi**

*Vector Control Research Centre  
Indian Council of Medical Research  
(Ministry of Health & Family Welfare,  
Govt. of India)  
Medical Complex, Indira Nagar  
India*

**Dr. Reyazul Rouf Mir**

*International Crops Research Institute for the Semi-Arid Tropics (ICRISAT),  
Patancheru - 502 324, Greater Hyderabad,  
India*

**Dr. Prasanna Kumar S**

*Virginia Commonwealth University,  
USA*

**Dr. Naseem Ahmad**

*Plant Biotechnology Laboratory  
Department of Botany  
Aligarh Muslim University  
Aligarh- 202 002, (UP)  
India*

**Dr. Zhen-Xing Tang**

*Food Bioengineering institute, Hangzhou Wahaha Co. Ltd, Hangzhou, Zhejiang, China*

**Dr. Jayanthi Abraham**

*VIT (Vellore Institute of Technology) University,  
Tamilnadu,  
India*

**Dr. Gobianand Kuppannan**

*National Institute of Animal Science  
South Korea*

**Dr. R. Harikrishnan**

*Jeju National University  
South Korea*

**Dr. Asit Ranjan Ghosh**

*Vellore Institute of Technology (VIT) University,  
School of Bio Sciences & Technology,  
Medical Biotechnology Division, Vellore-632014,  
India*

**Dr. Kamal Dev**

*Shoolini University of Biotechnology and Management Sciences (SUBMS)  
India*

**Dr. Wichian Sittiprapaporn**

*Maharakham University  
Thailand*

**Dr. Vijai Kumar Gupta**

*Molecular Glycobiotechnology Group, Department of Biochemistry,  
School of Natural Sciences,  
National University of Ireland, Galway,  
Ireland*

**Dr. Jeffy George**

*Department of Microbiology and Immunology  
F. Edward Hébert School of Medicine  
Uniformed Services University of the Health Sciences  
4301 Jones Bridge Road,  
Bethesda, MD 20814  
USA.*

**Dr. Gyanendra Singh**

*Stanley S. Scott Cancer Center,  
School of Medicine,  
Louisiana State University Health Sciences Center  
New Orleans, LA 70112,  
USA.*

**Dr. Anupreet Kour**

*1620 Chevy Chase Dr.  
Champaign, IL 61821  
USA.*

**Dr. Arun Sharma**

*Institute for Plant Genomics and Biotechnology (IPGB)  
Borlaug Center,  
TAMU 2123  
Texas A&M University  
College Station, TX 77843  
USA.*

**Dr. Mohsen Asker**

*Microbial Biotechnology Dept.  
National Research Centre  
Cairo,  
Egypt.*

**Dr. Elijah Miinda Ateka**

*Department of Horticulture,  
Jomo Kenyatta University of Agriculture and  
Technology (JKUAT)  
Kenya.*

**Dr. Jozélio Freire De Carvalho**

*Faculdade de Medicina Da USP, Reumatologia  
Av. Dr. Arnaldo, 455 - 3º andar – Sala 3133.  
São Paulo - SP  
Brazil*

**Dr. Premendra Dhar Dwivedi**

*Food Toxicology Division  
Industrial Institute of Toxicology Research,  
Post Box No: 80, Mahatma Gandhi Marg,  
Lucknow 226001,  
India*

**Dr. Muhammad Abd El-Moez El-Saadani**

*Universities and Research Center District,  
New Borg El-Arab,  
P.O.Box: 21934 Alexandria,  
Egypt.*

**Dr. Donald J. Ferguson**

*Advanced Orthodontic Training Program,  
Nicolas & Asp University College  
Dubai,  
UAE*

**Dr. Kalyan Goswami**

*Department of Biochemistry & JB Tropical Disease  
Research Centre,  
Mahatma Gandhi Institute of Medical Sciences,  
Sevagram, Wardha-442102*

**Dr. A.K. Handa**

*National Research Centre for Agroforestry,  
Gwalior Road, JHANSI-284003 UP  
India.*

**Dr. Amjad M.Husaini**

*Metabolic Engineering & Biotechnology Laboratory  
Division of Plant Breeding & Genetics  
Sher-e-Kashmir University of Agricultural Sciences &  
Technology of Kashmir  
J&K-191121,  
India*

**Dr. Vinod Joshi**

*Laboratory of Virology & Molecular Biology,  
Desert Medicine Research Centre,  
Pali Road, Jodhpur-342 005,  
India*

**Dr. T. Kalaivani**

*D/O S. Thiagarajan  
B-43, Rajaram Nagar,  
Salem - 636 007,  
Tamil Nadu, India*

**Dr. Priya Kalia**

*Orthopaedic Research Unit,  
Department of Surgery,  
Cambridge University, Cambridge,  
UK*

**Dr. Patricia Khashayar**

*Tehran University of Medical Sciences  
Endocrinology and Metabolism Research Center  
Shariati Hospital*

**Dr. Zaringhalam Moghadam**

*Shahid Beheshti Medical University (M.C)  
Tehran,  
Iran*

**Dr. Okeke Ikechukwu Linus**

*Department of Surgery, University of Ibadan  
Nigeria.*

**Dr. Rajesh Kumar Patel**

*Centre for Analysis and Learning in Livestock and Food  
(CALF)  
National Dairy Development Board (NDDB)  
Anand- 388 001 (Gujarat)  
INDIA*

**Dr. Pooja Ralli-Jain**

*Department of Pathology and Laboratory Medicine  
University of California Irvine,  
Irvine, California,  
U.S.A.*

**Dr. Meltem Sesli**

*College of Tobacco Expertise,  
Turkish Republic, Celal Bayar University 45210,  
Akhisar, Manisa,  
Turkey*

**Dr. Reda H. Sammour**

*Tanta University, Faculty of Science, Tanta,  
Egypt*

**Dr. Seyed Soheil Saeedi Saravi**

*Mazandaran University of Medical sciences, Sari,  
Iran*

**Dr. R. Senthil Kumar**

*St. Matthew's University, School of Medicine  
Grand Cayman  
Cayman Islands*

**Dr. Mohammad Reza Shakibaie**

*Kerman University of Medical Sciences, Kerman,  
Iran*

**Dr. Srividya Shivakumar**

*Dept of Microbiology,  
CPGS, Jain university,  
Bangalore*

**Dr. Shashideep Singhal**

*The Brooklyn Hospital Center  
NewYork-Presbyterian Healthcare System  
Brooklyn,  
NY.*

**Dr. Sripada M. Udupa**

*International Center for Agricultural Research in the  
Dry Areas (ICARDA),  
B.P. 6299, Rabat Instituts, Rabat,  
Morocco.*

**Dr. Wei Wu**

*Institute for Biocomplexity and Informatics  
Department of Bio Science  
The University of Calgary  
Canada*

**Dr. Xiao-Bing Zhang**

*Molecular Regeneration Laboratory, MC1528B  
11234 Anderson Street  
Loma Linda, CA 92350*

**Prof. Dr. Ozfer Yesilada**

*Inonu University  
Faculty of Arts and Sciences  
Department of Biology  
44280 Malatya  
Turkey*

**Dr. Edson Boasquevisque**

*Universidade do Estado do Rio de Janeiro- UERJ  
Av 28 de setembro, 87, fundos (LMMC-IBRAG).  
Vila Isabel, city: Rio de Janeiro/ RJ  
Brasil*

**Dr. Abhilash M.**

*The Oxford College of Engineering  
Hosur Road, Bangalore - 560068*

**Dr. Nasar Uddin Ahmed**

*Department of Genetics and Plant Breeding  
Patuakhali Science and Technology University  
Dumki, Patuakhali-8602  
Bangladesh*

**Dr. Mervat Morsy EL- Gendy**

*Chemistry of Natural and Microbial Products  
Department,  
National Research Center, Dokki, Cairo,  
Egypt*

**Dr. Gjumarakch Aliev**

*Health Science and Healthcare Administration  
Program,  
University of Atlanta, Atlanta, Georgia,  
USA*

**Dr. Muhammad Asgher**

*Department of Chemistry and Biochemistry,  
University of Agriculture,  
Faisalabad,  
Pakistan*

**Dr. Anand Bharatkumar**

*Parul Institute of Pharmacy, Limda, Waghodia,  
Vadodara*

**Dr. Chinmoy Kumar Bose,**

*Netaji Subhash Chandra Bose Cancer Research  
Institute  
16A, Park Lane, Park Street, Kolkata 700 016,  
India.*

**Dr. Mousumi Debnath**

*Jaipur Engineering College and Research Centre  
(JECRC) Department of Biotechnology,  
Shri Ram ki Nangal, Via Vatika ,Tonk Road , Jaipur-  
303905 ,  
India*

**Dr. Dolan C. Saha**

*Dept. of Biochemistry and Molecular Biology,  
Faculty of Medicine,  
University of Calgary,  
Canada*

**Dr. Ramasamy Harikrishnan**

*Department of Aquatic Biomedical Sciences  
School of Marine Biomedical Science  
College of Ocean Sciences  
Jeju National University  
Jeju city, Jeju 690 756,  
South Korea*

**Dr. Abdul Haque**

*Health  
Biotechnology division, nibge,  
Faisalabad,  
Pakistan*

**Dr. Kuvalekar Aniket Arun**

*Interactive Research School for Health Affairs  
(IRHSA),  
Bharati Vidyapeeth University, Pune, Maharashtra,  
India*

**Dr. Asit Ranjan Ghosh**

*School of Bio Science & Technology,  
Division of Medical Biotechnology,  
Vellore Institute of Technology (VIT) University,  
Vellore-632014,  
India*

**Dr. Prasanna Kumar Santhekadur**

*Department of Human and Molecular Genetics  
Virginia Commonwealth University  
Richmond,  
VA*

**Dr. Majid Sattari**

*Rice Research Institute of Iran  
Iran*

**Dr. Mihael Cristin Ichim**

*National Institute Research and Development for  
Biological Sciences /  
"Stejarul" Research Centre for Biological Sciences  
Alexandru cel Bun St., 6, Piatra Neamt, 610004,  
Romania*

**Dr. Sailas Benjamin**

*Enzyme Technology Laboratory  
Biotechnology Division  
Department of Botany  
University of Calicut  
Kerala - 673 635  
India*

**Dr. Sreeramanan Subramaniam**

*School of Biological Sciences,  
Universiti Sains Malaysia (USM),  
Minden Heights, 11800, Penang,  
Malaysia*

**Dr. Vijai Kumar Gupta,**

*Department of Biochemistry, NUI, Galway,  
Ireland*

**Dr. Vitor Engrácia Valenti**

*Universidade Federal de São Paulo  
Rua Napoleão de Barros, 715, Térreo  
São Paulo, SP  
Brazil.*

**Dr. Ravindra Pogaku**

*School of Engineering and IT  
Universiti Malaysia Sabah  
88999 Kota Kinabalu  
Sabah,  
Malaysia*

**Dr. Ahmed Eid Abdel-Hamid Eweis Fazary**

*School of Pharmacy,  
College of Medicine,  
National Taiwan University, Taipei 100,  
Taiwan.*

**Dr. Mohammad Hashemi**

*Dept. of Clinical Biochemistry,  
School of Medicine,  
Zahedan University of Medical Sciences,  
Zahedan,  
Iran*



**Dr. Hesham, Abd El-Latif**

*Genetics Department,  
Assiut University, Assiut 71516,  
Egypt.*

**Prof. Jia-ying Xin**

*College of Food Engineering  
Harbin University of Commerce  
138 Tongda Road  
Daoli District  
Harbin 150076, Heilongjiang  
P.R.China*

**Dr. Kabir Mohammad Humayun**

*Plant Molecular Biotech Lab  
Department of Medical Biotechnology  
College of Biomedical Science  
Kangwon National University  
Kangwon-do, Chuncheon, 200-701  
South Korea*

**Dr. Kalpesh Gaur**

*Geetanjali College of Pharmaceutical Studies Manwa  
Khera,  
Udaipur- 313002. Rajasthan,  
India*

**Dr. Meganathan, Kannan**

*Center for Biologics Evaluation and Research (CBER),  
U.S. Food and Drug Administration (FDA),  
Bldg. NIH 29A, Room 2C-10,  
8800 Rockville Pike,  
Bethesda, MD 20892.  
USA.*

**Assist. Prof. Ali Karadeniz**

*Department of Physiology,  
Faculty of Veterinary Medicine,  
University of Atatürk 25240 ERZURUM  
Turkey*

**Dr. Matthew Kostek**

*Department of Kinesiology  
University of Connecticut  
Storrs CT*

**Dr. Tansu Kucuk**

*Gulhane School of Medicine  
Department of Obstetrics and Gynecology  
Etlik 06018 Ankara,  
Turkey*

**Dr. Kuo-Sheng Hung**

*Department of Neurosurgery  
Taipei Medical University - Wan Fang Medical Center  
111 Section 3, Hsing-Long Rd,  
Taipei 116,  
Taiwan*

**Dr. V. Manju**

*Department of Biochemistry,  
Periyar University,  
Salem -11.*

**Dr. Mbagwu Ferdinand Nkem**

*Department of Plant science and Biotechnology,  
Faculty of Science,  
Imo State University  
Nigeria.*

**Dr. Anand Pithadia**

*Parul Institute of Pharmacy  
Vadodara, Gujarat,  
India*

**Dr. Radhakrishnan Ramaraj**

*Department of Internal Medicine  
University of Arizona  
Tucson 85724  
AZ*

**Dr. M. Rasool**

*School of Bio Sciences and Technology,  
VIT University,  
Vellore-632104, Tamil Nadu,  
India*

**Dr. Reda A.I. Abou-Shanab**

*Genetic Engineering & Biotechnology Research  
Institute (GEBRI)  
Mubarak City for Scientific Research and Technology  
Applications  
New Burg El-Arab City, Universities and Research  
Institutes  
Zone, P.O. 21934, Alexandria,  
Egypt.*

**Dr. MR. Pravin Babarao Suruse**

*Department of Pharmaceutics  
Sharad Pawar College of Pharmacy  
Wanadongri, Hingna Road  
Nagpur- 441 110. (M. S.)*

**Dr. Jan Woraratanadharm**

*GenPhar, Inc.,  
Mount Pleasant,  
SC*

**Dr. Serap Yalin**

*Mersin University Pharmacy Faculty  
Department of Biochemistry, Mersin  
Turkey*

**Dr. YongYong Shi**

*Bio-X Center,  
Shanghai Jiao Tong University,  
Hao Ran Building, 1954 Hua Shan Road,  
Shanghai 200030,  
PR China*

**Dr. Jyotdeep Kaur**

*Department of Biochemistry,  
Post Graduate Institute of Medical Education and  
Research (PGIMER),  
Chandigarh*

**Dr. Rajkumar**

*Dept. Of Radiation Biosciences,  
Institute of Nuclear Medicine and Allied Sciences  
Brig. S.K. Mazumdar Road, Timarpur,  
Delhi-110054  
India*

**Dr. Meera Sumanth**

*Visveswarapura Institute of Pharmaceutical Sciences,  
22nd Main, 24th Cross, B.S.K II stage,  
Bangalore-560070  
Karnataka,  
India.*

**Dr, Jai S. Ghosh**

*Department of Microbiology,  
Shivaji University,  
Kolhapur 416004,  
India*

**Prof. Dr. Alaa H. Al-Charrakh**

*Babylon University, College of Medicine.  
Dept. of Microbiology  
Hilla, Iraq*

**Table of Contents: Volume 7 Number 4 October, 2016**

**ARTICLE**

<b>Studies on various types of antigenic proteins of Fasciola spp. as a basis for the immunodiagnosis and vaccine development: A review</b>	<b>36</b>
J. S. Dar, I. Tak, B. A. Ganai and R. A. Shahardar	

## Review

# Studies on various types of antigenic proteins of *Fasciola* spp. as a basis for the immunodiagnosis and vaccine development: A review

J. S. Dar<sup>1</sup>, I. Tak<sup>1\*</sup>, B. A. Ganai<sup>1</sup> and R. A. Shahardar<sup>2</sup>

<sup>1</sup>Centre of Research for Development, University of Kashmir, Srinagar, 190 006, India.

<sup>2</sup>Department of Veterinary Parasitology, SKUAST, Kashmir, India.

Received 16 October, 2015; Accepted 4 December, 2015

*Fasciola* spp. is responsible for huge economic losses and animal welfare issues within the agricultural sector worldwide. Protein profiling studies of the two economically important species of *Fasciola*, that is, *Fasciola hepatica* and *Fasciola gigantica* are important for identification of these species, their immunodiagnosis and also for vaccine designing. Protein profiling is expected to discover a number of target proteins for the purpose of drug designing and vaccine development by determining the function of thousands of unidentified proteins still likely to be found in the genome of *F. hepatica* and *F. gigantica*. Electrophoretic protein profiling is expected to multiply the number of known drug targets 100-fold. Different immunodiagnostic tests such as enzyme linked immunosorbant assay (ELISA), immunofluorescence and agglutination tests have been used in the early immune diagnosis of fasciolosis, but they have some disadvantages, such as cross reactions with other trematodes, leading to false positive results. In recent years, SDS-PAGE and Western blot procedures have created a new era in immunodiagnosis, and greatly reduced cross reactions. Over the last two decades, various studies to identify and characterize proteins of immunological significance have been carried out, especially the candidates for immunodiagnosis or vaccination in fasciolosis. Recent research indicates that a future prospect for the control of fasciolosis by immunological intervention appears brighter than previously thought. This paper reviews the principles of proteomics, as well as its key instruments and research applications in helminthology, including host parasite interactions, vaccine development and diagnosis of liver fluke diseases and encourage more young researchers to initiate work on the molecular aspects of these economically cosmopolitan parasites.

**Key words:** *Fasciola hepatica*, *Fasciola gigantica*, vaccines, ELISA, SDS-PAGE, Western blot.

## INTRODUCTION

Liver fluke disease or fasciolosis is an economically important disease of sheep and cattle worldwide. *Fasciola* spp. parasitize a wide spectrum of domestic and wild animals (e.g., sheep, cattle, buffaloes and deer) and

cause a huge economic loss of \$3 billion annually to the agriculture sector worldwide through losses of milk and meat yields (Robinson et al., 2009). In addition, fasciolosis is now recognized as an emerging human

disease. The World Health Organization (WHO, 2006) has estimated that 2.4 million people are infected with *Fasciola hepatica* and a further 180 million are at risk of infection. Adult parasites of these flukes are found in the bile ducts and the immature flukes in the liver parenchyma, of infected final hosts. The immature flukes migrate in the liver hepatic tissue after penetrating the liver capsule. This migration is usually associated with trauma, hemorrhages and necrosis, finally leading to liver cirrhosis (Ozer et al., 2003). The diagnosis of fasciolosis is very important for its control, parasitological diagnosis in this respect is however often unreliable because the parasite eggs are not found during the prepatent period (Nour Eldin et al., 2004). Even when the worms have matured, the diagnosis may still be difficult because the eggs are only intermittently released. Early diagnosis of liver fluke infection is necessary for its prompt treatment before irreparable damage of the liver occurs (Rokni et al., 2004). For these reasons, immunological and molecular techniques are the most dependable diagnostic methods. Attempts have been made to diagnose sheep fasciolosis by detecting antibodies in the serum patient suspected of being infected with the flukes (Maleewong et al., 1999). Advances in immunodiagnosis have focused on detection of parasite antigens in host body fluids and faeces; these tests have an advantage over antibody detection because antigenemia implies recent and active infection (Cornelissen et al., 1999). Similarly, somatic and excretory-secretory (E/S) antigens of liver flukes or their partially purified component are the commonest source of antigens used in protection trials and serodiagnosis (Gnen et al., 2004). Several methods have been developed for the immunological diagnosis of human fasciolosis. Enzyme linked immunosorbant assay is both a sensitive and reliable means of diagnosing the acute and chronic stages of human fasciolosis (Hillyer et al., 1992). Previously developed ELISA methods have been employed for crude somatic antigen or liver fluke excretory-secretory (E/S) products to detect anti-fluke antibodies in serum (Knobloch et al., 1985). These antigen preparations are complex and may result in reduced specificity of the assay since many parasites share similar antigens. Previous work in the laboratory led to the isolation and characterization of cathepsin LI, a major molecule of ES products. This molecule has been shown to be highly immunogenic in infected animals (Dowd et al., 1994). The diagnosis of parasite infection in domestic ruminants has recently been directed towards the detection of parasite antigens in host body fluids (Guobadia and Fagbemi, 1995). Antigen detection assays have several advantages over other methods and

they can identify animals with prepatent or occult infections, which were undetected by the usual parasitological tests. Moreover, they can give a more accurate indication of current infection rather than past infection (Zheng et al., 1990). In recent years, SDS-PAGE and Western blot procedures have created a new era in immunodiagnosis, and greatly reduced cross reactions. Analysis of cross-reactivity among digenetic trematodes is of paramount importance for understanding the evolutionary conservation of antigens and for the development of sensitive and specific serodiagnostic assays. However, the extent to which these antigens cross-react with other related parasites remains to be investigated.

### APPLICATION OF PROTEOMICS FOR DIAGNOSIS OF FASCIOSIS

Common methods for the diagnosis of fasciolosis diseases are based on old-fashioned technologies like microscopy. The microscopic detection of parasites is performed on different types of specimen, e.g. blood smears, tissue and feces. Parasitological diagnosis of fasciolosis is possible only after 13 to 14 weeks post-infection by demonstrating fluke eggs in faeces. By this time, major damages to the host hepatic system may have already occurred. Moreover, sample preparation is both time-consuming and laborious work, and efficiency of diagnosis depends on the abilities of laboratory technicians. After the recent emergence of proteomics-based approaches, biomarker discovery has continued to develop and is now being applied in the diagnosis of parasitic diseases. Protein biomarkers reveal the existence and biological state of a particular organism. Diagnosis of fasciolosis is usually confirmed during the chronic phase of the disease when worms are established in the bile ducts and started to produce eggs. Fortunately, a number of serological tests such as ELISA (Burden and Hammet, 1978) and Western blot (Duffus and Franks, 1981) are useful in detection of infection, particularly in the prepatent period. However, these tests need selection of powerful antigens that recognize the infection during the early stage of its development. The serodiagnostic methods for the detection of antibodies are quite sensitive in detecting the infection in the early stages and have been exploited for the diagnosis of fasciolosis (Sanitago et al., 1986). Serological methods also have major limitations of detecting antibodies of previous exposure to the infection in treated animals. For this reason, careful analysis of the parasite antigenic

\*Corresponding author. E-mail: irfanrauftak@yahoo.in.

structure is required for accurate early diagnosis.

### Candidate antigens of *Fasciola* spp. for immunodiagnosis

Studies have already been carried out on the antigenic composition of *F. hepatica*. Proteins within the molecular weight ranges of 27 and 30 kDa, are common to E/S and somatic preparations in both parasite preparations of *Fasciola* spp. (Ajanusi et al., 1993). Hence, these fractions of proteins could be essential for the purpose of diagnosis of Fasciola infection in animals. Sobhon et al. (1996) analyzed the proteins from the homogenized whole body of *F. gigantica*: it was found that there were approximately 21 detectable bands, ranging in molecular weight from 17 to 110 kDa. Eleven of the bands at 97, 86, 66, 64, 58, 54, 47, 38, 35, 19 and 17 kDa, were present in the tegument antigen which were extracted from the parasites bodies by Triton X-100. By immunoblotting analysis, Sobhon et al. (1996) found that 14 of the 21 bands of the whole body fraction were antigenic, while all 11 bands of the tegument-associated proteins were antigenic: the major antigens were 4 bands at 66, 58, 54 and 47 kDa. In comparison, there has been considerable study on *F. hepatica*. Itagaki et al. (1995) found that the major antigens of adult *Fasciola* spp. were at 64-52, 38-28, 17, 15, 13, and 12 kDa; it was also reported that the antigens at 66, 58 and 54 kDa were more species-specific, they might be possible candidates for serodiagnosis of fasciolosis in cattle.

The immunodiagnosis of animal fasciolosis by the detection of circulating antigens has not yet been thoroughly investigated. Fegbemi et al. (1995) successfully used rabbit antibodies against the 88 kDa antigen of adult *F. gigantica* for the detection of circulating antigens in experimentally-infected cattle sera. Viyanant et al. (1997) studied a monoclonal antibody specific to a 66 kDa antigen of *F. gigantica* for the detection of circulating antigens in experimentally- and naturally-infected cattle: they reported that circulating antigens could be detected as early as the second and third weeks after infection; these antigens were associated with the crude surface tegument of the parasite. A 28 kDa protein present in E/S products of adult parasites was also identified by Ruiz Navarrete et al. (1993). This protein corresponds to cysteine-L-proteinase which was identified and purified by Dalton et al. (1996) and separated from the E/S products of *F. hepatica*. Furthermore, important enzymatic components, such as glutathione-S-transferase (Hillyer et al., 1992), haemoglobinase (Coles and Rubano, 1988) and cysteine-L-proteinases of *F. hepatica* (Smith et al., 1993; Dowd et al., 1994) have been identified within the 27.5 to 29 kDa range in E/S products of the parasite. Cysteine proteinases of the E/S products of Fasciola have become

the focus of research since they play important biological and immuno-modulatory functions in the juvenile and adult parasites (Chapman and Mitchell, 1982; Smith et al., 1993). Moreover, these proteinases have also been shown to induce a high protective immunity in experimentally infected cattle (Dalton et al., 1996). A protein of 12.5 kDa is also separated; it corresponds to SAP2 protein which is proved to have protective potentiality against *F. hepatica* infection (Espino and Hillyer, 2003; Hillyer, 2005). Excretory-secretory (E/S) antigens have more contact with the host immune system than somatic antigens, since the parasite excretes the content of the intestine like cathepsins and other enzymes with cytolytic activities. These enzymes degrade tissues and facilitate the invasion and migration of the parasite, and induce a stronger humoral immune response, useful for diagnostic purposes and also for protection against future infections (Dalton et al., 1989; Parkhouse et al., 1987).

### Application of proteomics for vaccine development strategies against fasciolosis

The rationale of vaccine designing in *Fasciola* spp. consists of three main strategies: First to identify those antigens of the parasite that are significantly different and do not show cross reactivity with those of hosts. Secondly, the selected antigens should be able to elicit strong immunological responses in hosts, such that the migrating juveniles could be immobilized or killed when they pass into the host's tissue. And thirdly, bulk syntheses of the antigens of choice should be feasible through the application of recombinant DNA cloning techniques. Immunoproteomics is important for discovering new antigens in vaccine development. This technique combines proteomics with the immunoreaction in order to identify potential vaccine candidates. Generally, in such techniques, protein lysate of a parasite is separated by 2D-gel electrophoresis, then blotted onto a membrane. The 2D-blot is probed with infected or immunized host serum. This technique enables the discovery of novel proteins involving stimulation of the host immune system.

Identifying vaccine candidates for parasite control has historically involved vaccinating host animals with crude extracts or whole organisms before fractionating these to identify the protective components. This is a costly and lengthy method often taking decades to complete (Knox, 2010). Crude somatic extracts of parasites can be prepared in a number of ways. Proteins solubilised at each step can be loosely described as water-soluble, membrane-associated and membrane-bound, respectively (Smith et al., 2000). Proteins within the membrane-bound fraction (Triton X-100 extract) have been a rich source of protective antigens against the

blood feeding nematode, *Haemonchus contortus* (Smith et al., 2000). The highly protective H-gal-GP complex was identified within this fraction. Furthermore, proteases have, historically, made good vaccine candidates against helminth parasites. For example, the main vaccine candidates, to date, against infection with *F. hepatica* are the proteases, cathepsin L1 and L2 (Dalton et al., 1996; Mulcahy and Dalton, 2001) and leucine aminopeptidase (LAP) (Acosta et al., 2008). LAP has elicited the highest protection, to date, of a single antigen against *F. hepatica*, where immunizing sheep reduces worm burden by up to 89%, or when used in combination with the cathepsin L1 and L2, which is up to 76% (Acosta et al., 2008).

Targeting secreted antigens released by parasites has been a popular starting point for vaccine studies (Smith, 1999). This method has identified antigens which have elicited protective immunity against a number of parasites including *F. hepatica*. These antigens are termed “natural” or “conventional” antigens as they are recognized by the host during the course of a natural infection (Smith, 1999). Native intestinal antigens have been purified, characterized and shown repeatedly to reduce both egg counts and worm burdens (Knox and Smith, 2001; Knox et al., 2003; Smith et al., 1999). Targeting “hidden” antigens could prove to be a novel and successful strategy for vaccinating against *F. hepatica* as the adult liver fluke lives in a highly vascularised environment and feeds on surrounding tissue.

### **Candidate antigens of *Fasciola* spp. for vaccine development strategies**

The vaccine development strategies against *F. hepatica* and the related parasite *F. gigantica* have shown enormous progress over the last three decades. Most vaccines may, however, not be as ideal as desired, because *Fasciola* spp. are large and complex with potential ability to tolerate any disturbance and capability to repair themselves. Even partial vaccines that could impair the penetration and migration of newly excysted juveniles or those that could reduce the fecundity of adult parasites would have beneficial effect in infected animals. Recent research indicates that future prospects for the control of fasciolosis by immunological intervention appear brighter than previously thought. Candidate antigens from *F. hepatica* and *F. gigantica* have shown vaccine potential during trials in cattle, sheep and rats. Interestingly, most of these vaccine candidates were first isolated as native proteins, usually from adult worm ES products, because this antigen preparation was not very complex and was easy to obtain. Several of these early antigens, including cathepsin L proteases, GST and fatty acid binding protein (FABP) induced significant protection

in cattle and sheep (Toet et al., 2014), reducing not only worm burden (and egg output), but also liver pathology. Recent reports of vaccine trials in sheep with several recombinant but functional forms of these antigens such as cathepsin L1 (CL1), GST and peroxiredoxin (FhPrx) from *F. hepatica*, or Sm14 peptide from *S. mansoni*, have not only reported significant reduction of worm burdens but have shown reduced liver pathology (Zafra et al., 2009, 2013a, b; Mendes et al., 2010; Perez-Ecija et al., 2010; LaCourse et al., 2012; Toet et al., 2014). Furthermore, recent genomics/transcriptomic data reveal these proteins belong to large families with complex developmental expression patterns that need to be explored further to ensure that the appropriate members are those that are brought into vaccine trials. The observation that adult worm-derived antigens can induce protection at the level of the liver (and possibly earlier) would suggest that these antigens are either also expressed by the juvenile/immature parasite stages or that the immune response cross-reacts between the various members of the same family.

### **Cathepsins L and B proteases of *Fasciola*: Importance and role as potential vaccine candidates**

*F. hepatica* relies on proteolytic activity for many of its pivotal functional activities in the host, including tissue penetration, migration, feeding and immune evasion and, hence, it is not surprising that these have been the most encouraging candidates for vaccine development for some time (Dalton et al., 2013). Adult parasites secrete an abundance of cathepsin L cysteine proteases, representing about 80% of the total protein from adult ES, that they use for digesting the protein contents of the blood, including haemoglobin, albumin and immunoglobulin, consistent with ES protein analysis (Wilson et al., 2011). This provides free amino acids required for synthesizing egg proteins (Robinson et al., 2008a). Cathepsin LI, one of the major molecules of fluke excretory-secretory product, is secreted at each stage in the development of the parasite, and has shown to be highly immunogenic in infected animals. This molecule has the ability to cleave host immunoglobulin and can inhibit *in vitro* attachment of eosinophils to newly excysted juveniles (Carmona et al., 1993). Cathepsin LI is also capable of degrading extracellular matrix and basal membrane components and thus aids in parasite migration through the tissue of the host (Berasain et al., 1997).

Native cathepsin L proteases are readily isolated from adult ES products by standard gel permeation and ion exchange chromatography into two ‘homogeneous’ fractions (termed FhCL1 and FhCL2) (Smith et al., 1993). The highly significant protection observed using these native preparations when delivered in Freund’s complete

adjuvant was further enhanced (72.4%) when combinations were made with proteins contained in a high molecular weight haem-containing (Hb) fraction. The Hb fraction itself induced low but significant protection (43.8%) in cattle against a challenge infection and recent proteomic analysis has revealed that this mixture includes peroxiredoxin (FhPrx), the helminth defense molecule (FhHDM) and fatty acid binding protein (FABP), all of which can induce modulation of host immune responses including alterations in macrophage function (Robinson et al., 2011b, 2012; Thivierge et al., 2013; Dalton et al., 2013; Figueroa-Santiago and Espino, 2014). Our understanding of *F. hepatica* proteases, and other secreted proteins, has been greatly improved by the availability of proteome data (Jefferies et al., 2001; Morphew et al., 2007; Robinson et al., 2008b; Robinson and Dalton, 2009) and by integrating this with an analysis of the transcriptome (Robinson and Dalton, 2009). The FhCL1 and FhCL2 are not expressed and secreted by the newly emerged juveniles (NEJ) as they penetrate the liver and intestine; these early-stage parasites produce different members of the cathepsin L family, FhCL3 and FhCL4. FhCL3 is particularly abundant and secreted by NEJ while FhCL4 may play a more housekeeping role (Cancela et al., 2008; Robinson et al., 2008b, 2009). The expression of FhCL3 is down-regulated soon after the parasite enters the liver parenchyma while FhCL1, FhCL2 and another family member, FhCL5, become more predominant as the parasite migrates and prepares to enter the bile ducts. These changes in protease expression reflect the parasite's adaptation to its changing environment as it migrates through different tissues and encounters new macromolecules. Molecular and biochemical analysis of FhCL3 (Corvo et al., 2009, 2013; Robinson et al., 2011a) have shown that this enzyme possesses a constellation of residues in its active site that confer it with a unique ability to digest collagen, suggesting that this protease is critical to parasite penetration of the intestine and liver capsule (Dalton et al., 2006).

Interestingly, a similar highly regulated pattern of expression occurs with the cathepsin B proteases. Cathepsin B-like proteolytic enzyme have been shown to cleave immunoglobulins of mice, rats and sheep *in vitro* (Chapman and Mitchell, 1982). Several cathepsin B proteases (FhCB1, FhCB2 and FhCB3) show parallel expression with the FhCL3, that is, are secreted by the early NEJ but are down-regulated as the parasite migrates in the liver tissue. This would suggest that the concerted action of FhCL3/FhCBs is essential for successful intestine and liver penetration.

It has been demonstrated (Dalton and Heffeman, 1989) that immature and mature flukes secrete endo-proteinases into culture medium when maintained *in vitro*. Several functions have been suggested for the role of these enzymes including functioning in migration through

host tissue (Dalton and Heffeman, 1989), the acquisition of nutrient (Smith et al., 1993) and evasion of host immune responses (Dalton and Heffeman, 1989). Two cysteine proteases were isolated and characterized as having physiochemical properties similar to the mammalian lysosomal cathepsin L proteinases (Dowd et al., 1994). The two enzymes were observed to differ in their specificities for hydrolysing peptide bonds (Dowd et al., 1994) and as a result, were termed cathepsin L1 and cathepsin L2. McGonigle and Dalton (1995) isolated another antigen containing a haem group from flukes maintained in culture medium, which was shown to be the liver fluke haemoglobin (Hb) (McGonigle and Dalton, 1995). It has been also observed that animals immunized with a thiol-cathepsin-related proteinase developed antibodies to the cysteine proteinase prior to infection with metacercaria of *F. hepatica*. On completion of the trial, there was no difference in worm burden between animals which had been immunized prior to infection and that of infected animals which did not receive the proteinase. However, fecal egg counts and therefore worm fecundity was significantly decreased in the immunized animals.

There are other trials that have been carried out by various scientists which resulted in the generation of a number of potential vaccine candidates that are listed in Table 1.

## CONCLUSION

In this review, the critical parameters of immunodiagnosis and vaccine development strategies against *Fasciola* spp., and the need for both scientific and organizational breakthroughs if the world is to meet the enormous challenge of eliminating this harmful parasite, were emphasized. Following the development and advancement of next-generation sequencing technologies, large sequence datasets have been generated for several parasites. Genome data sets can inform functional genomics analysis, including transcriptomics, proteomics, secretomics and epigenomics. Utilizing all available 'omics' data for a particular parasite provides an unbiased approach to understanding parasite biology, rather than focusing on a particular gene or protein. The recent progress in immunodiagnostic methods has enabled the detection of fasciolosis at early stages of infection. Different immunodiagnostic tests have been used in the early immune diagnosis of fasciolosis, but they have some disadvantages, such as cross reactions with other trematodes, leading to false positive results. In recent years, SDS-PAGE and Western blot procedures have created a new era in immunodiagnosis, and greatly reduced cross reactions. Over the last few decades, much progress has been made in the isolation,



**Table 1.** Vaccination trials carried out by various workers.

Trial research	Species	Antigen	Reduction fluke burden (%)
Dalton et al., 1996	Cattle	FhCL1, FhCL2	53.7
		FhCL1+FHb FhCL2+FHb	72.4
Mulcahy et al., 1998	Cattle	FhCL2+FHb	72
Piacenza et al., 1999	Sheep	FhCL1, FhCL2	33
		FhCL1+FhCL2	60
Kofta et al., 2000	Rats	cDNA encoding Fh.Cysteine protease	74
Wedrychowicz et al., 2003	Calves	cDNA intranasally	54.2
	Lambs		56.5
Golden et al., 2010	Cattle	rmFhCL1	48.2

characterization and testing of a number of native and recombinant molecules as vaccines against liver fluke disease in ruminant hosts. Indeed, it is important that as we move forward within the research field, a standardized vaccine protocol is established to allow comparison of results between trials. For the same reason, as new immunological reagents become available to improve the analysis of ruminant immune responses, it is critical that we develop standard operation procedures (SOPs) for both sheep and cattle, and other species. Many vaccine trial protocols involve sacrificing animals at the chronic stage of infection when the challenge parasites are in the bile ducts and easily recovered. However, at this time point, liver damage cannot be easily graded as it contains both acute- and chronic-associated damage. Perhaps, we should consider placing a greater importance on diagnostic methods of hepatic pathology, so that protection against liver disease at early stages of infection can be quantified: such as estimating liver enzymes in serum (aspartatetransaminase: AST, alkaline phosphatase: ALP, gamma-glutamyl transferase: GGT and glutamate dehydrogenase: GLDH) or finding novel serum biomarkers, that indicates several serological markers could be used for assessing liver damage. The pursuit of a *F. hepatica* vaccine needs to focus on understanding fluke biology, specifically the proteins involved in the tissue invasion and migration within the definitive host. It is our opinion that the most effective vaccine would be one that is directed against the early migratory stages of the parasite, including surface tegumental proteins/glycoproteins and secreted molecules, with the primary aim of preventing the penetration of the liver capsule by the parasites. This presents us with the challenge of learning more about the early migratory stages of *F. hepatica*, a stage that has traditionally been neglected, particularly in ruminants, due to the difficulty of obtaining workable levels of parasite material. However, genomic, transcriptomic and proteomic methods have made the molecular dissection

of this parasite stage possible and will facilitate the rational design of single and multiple antigen vaccine cocktails. It is imperative that we bolster this molecular progress with new methodologies and by combining robust immunological analysis of innate and adaptive responses with pathological analysis of the early stages of infection, to understanding how and when the parasite initiates control of host immune responses.

### Conflict of Interests

The authors have not declared any conflict of interests.

### ACKNOWLEDGEMENT

The authors thank the Centre of Research for Development (CORD), University of Kashmir for providing all the necessary facilities for conducting the research work.

### REFERENCES

- Acosta D, Cancela M, Piacenza L, Roche L, Carmona C, Tort JF (2008). *Fasciola hepatica* leucine aminopeptidase, a promising candidate for vaccination against ruminant fasciolosis. *Mol. Biochem. Parasitol.* 158:52-64.
- Ajanusi OJ, Harrison LJS, Sewell MMH (1993). *Fasciola hepatica*: Biosynthetic radio-labelling and Western Blot analysis of excretory-secretory product. *Trans. R. Soc. Trop. Med. Hyg.* 87:118.
- Berasain P, Goni F, McGonigle S, Dowd A, Dalton JP, Frangione B, Carmona C (1997). Proteases secreted by *Fasciola hepatica* degrade extracellular matrix and basement membrane components. *J. Parasitol.* 83:1-5.
- Burden DJ, Hammett NC (1978). Microplate enzyme linked immunosorbent assay for antibody to *Fasciola hepatica* in cattle. *Vet. Rec.* 103:158.
- Cancela M, Acosta D, Rinaldi G, Silva E, Duran R, Roche L, Zaha A, Carmona C, Tort JF (2008). A distinctive repertoire of cathepsins is expressed by juvenile invasive *Fasciola hepatica*. *Biochem.* 90(10):1461-1475.

- Carmona C, Dowd AJ, Smith AM, Dalton JP (1993). Cathepsin L protease secreted by *Fasciola hepatica* in vitro prevents antibody-mediated eosinophil attachment to newly excysted juveniles. *Mol. Biochem. Parasitol.* 62:9-17.
- Chapman CB, Mitchell GF (1982). Proteolytic cleavage of immunoglobulins by enzymes released by *Fasciola hepatica*. *Vet. Parasitol.* 11:165-178.
- Cornelissen JBWJ, Gaasenbeek CPH, Boersma W, Borgsteede FHM, Van Milligen, FJ (1999). Use of pre-selected epitope cathepsin-L1 in a highly specific peptide-based immunoassay for the diagnosis of *Fasciola hepatica* infection in cattle. *Int. J. Parasitol.* 29:685-696.
- Corvo I, Cancela M, Cappetta M, Pi-Denis N, Tort JF, Roche L (2009). The major cathepsin L secreted by the invasive juvenile *Fasciola hepatica* prefers proline in the S2 subsite and can cleave collagen. *Mol. Biochem. Parasitol.* 167(1):41-47.
- Corvo I, O'Donoghue AJ, Pastro L, Pi-Denis N, Eroy-Reveles A, Roche L, McKerron JH, Dalton JP, Craik CS, Caffrey CR, Tort JF (2013). Dissecting the active site of the collagenolytic cathepsin L3 protease of the invasive stage of *Fasciola hepatica*. *PLoS Negl. Trop. Dis.* 7(7):e2269.
- Dalton JP, Heffernan M (1989). Thiol proteases released in vitro by *Fasciola hepatica*. *Mol. Biochem. Parasitol.* 35:161-166.
- Dalton JP, McGonigle S, Rolph TP, Andrews SJ (1996). Induction of protective immunity in cattle against infection with *Fasciola hepatica* by vaccination with cathepsin L proteases and with hemoglobin. *Infect. Immun.* 64:5066-5074.
- Dalton JP, Caffrey C, Sajid M, Stack C, Donnelly S, Loukas A, Don T, McKerron J, Halton DW, Brindley PJ (2006). Proteases in trematode biology. In: Maule, A. G., Marks, N. J. (Eds.), *Parasitic Flatworms: Molecular Biology, Biochemistry, Immunology and Physiology*. CABI International, pp. 348-369.
- Dalton JP, Robinson MW, Mulcahy G, O'Neill SM, Donnelly S (2013). Immunomodulatory molecules of *Fasciola hepatica*: candidates for both vaccine and immunotherapeutic development. *Vet. Parasitol.* 195(3-4):272-285.
- Dowd AJ, Smith AM, McGonigle S, Dalton JP (1994). Purification and characterisation of a second cathepsin L proteinase secreted by the parasitic trematode *Fasciola hepatica*. *Eur. J. Biochem.* 223(1):91-98.
- Duffus WP, Franks D (1981). The interaction *in vitro* between bovine immunoglobulin and juvenile *Fasciola hepatica*. *Parasitol.* 82:1-10.
- Espino AM, Hillyer GV (2003). Molecular cloning of a member of the *Fasciola hepatica* saposin-like protein family. *J. Parasitol.* 89:545-552.
- Figueroa-Santiago O, Espino AM (2014). *Fasciola hepatica* fatty acid binding protein induces the alternative activation of human macrophages. *Infect. Immun.* 82(12):5005-5012.
- Gnen B, Sarimehmetolu HO, Koro M, Kiracali F (2004). Comparison of crude and excretory-secretory antigens for the diagnosis of *Fasciola hepatica* in sheep by western blotting. *Turk. J. Vet. Anim. Sci.* 28:943-949.
- Golden O, Flynn RJ, Read C, Sekiya M, Donnelly SM, Stack C, Dalton JP, Mulcahy G (2010). Protection of cattle against a natural infection of *Fasciola hepatica* by vaccination with recombinant cathepsin L1 (rFhCL1). *Vaccine* 28:5551-5557.
- Guobadia EE, Fagbemi BO (1995). Immunodiagnosis of fasciolosis in ruminants using a 28 kDa cysteine protease of *Fasciola gigantica* adult worms. *Vet. Parasitol.* 57:309-318.
- Hillyer GV, Soler de Galanes M, Rodríguez-Perez J, Bjorland J, Silva de Lagrava M, Ramirez Guzman S, Bryan RT (1992). Use of the Falcon assay screening test-Enzyme-Linked Immunosorbent Assay (fast-ELISA) and the Enzyme-linked Immuno-electrotransfer Blot (ET1B) to determine the prevalence of human Fasciolosis in the Bolivian Altiplano. *Am. J. Trop. Med. Hyg.* 46:603-609.
- Hillyer GV (2005). *Fasciola* antigens as vaccines against fascioliasis and schistosomiasis. *J. Helminthol.* 79:241-247.
- Itagaki T, Sakamoto T, Itagaki H (1995). Analysis of *Fasciola* sp antigen by enzyme-linked immunotransfer blot using sera from experimentally and naturally infected cattle. *J. Vet. Med. Sci.* 57:511-513.
- Jefferies JR, Campbell AM, van Rossum AJ, Barrett J, Brophy PM (2001). Proteomic analysis of *Fasciola hepatica* excretory-secretory products. *Proteom.* 1(9):1128-1132.
- Knobloch J, Delgado AE, Alvarez A, Reymann U, Bialek R (1985). Human fascioliasis in Cajamarca/Peru I: Diagnostic methods and treatment with praziquantel. *Trop. Med. Parasitol.* 36:88-90.
- Knox DP, Smith WD (2001). Vaccination against gastrointestinal nematode parasites of ruminants using gut-expressed antigens. *Vet. Parasitol.* 100:21-32.
- Knox DP (2010). Parasite Vaccines: Recent Progress in, and Problems Associated with their Development. *Open Infect. Dis. J.* 4:63-73.
- Knox DP, Redmond DL, Newlands GF, Skuce PJ, Pettit D, Smith WD (2003). The nature and prospects for gut membrane proteins as vaccine candidates for *Haemonchus contortus* and other ruminant trichostrongyloids. *Int. J. Parasitol.* 33:1129-1137.
- Kofta W, Mieszczanek J, Płucienniczak G, Wędrychowicz H (2000). Successful DNA immunisation of rats against fasciolosis. *Vaccine* 18:2985-2990.
- La Course EJ, Perally S, Morphew RM, Moxon JV, Prescott M, Dowling DJ, O'Neill SM, Kipar A, Hetzel U, Hoey E, Zafra R, Buffoni L, Perez Arevalo J, Brophy PM (2012). The sigma class glutathionetransferase from the liver fluke *Fasciola hepatica*. *PLoS Negl. Trop. Dis.* 6(5):e1666.
- Maleewong W, Wongkhan C, Intapan PM, Pipitgool V (1999). *Fasciola gigantica* specific antigens: purification by a continuous-elusion method and its evaluation for the diagnosis of human Fascioliasis. *Anim. J. Trop. Med. Hyg.* 61:648-651.
- McGonigle S, Dalton JP (1995). Isolation of *Fasciola hepatica* haemoglobin. *Parasitol.* 111:209-215.
- Mendes RE, Perez-Ecija RA, Zafra R, Buffoni L, Martinez-Moreno A, Dalton JP, Mulcahy G, Perez J (2010). Evaluation of hepatic changes and local and systemic immune responses in goats immunized with recombinant Peroxiredoxin (Prx) and challenged with *Fasciola hepatica*. *Vaccine* 28(16):2832-2840.
- Morphew RM, Wright HA, La Course EJ, Woods DJ, Brophy PM (2007). Comparative proteomics of excretory-secretory proteins released by the liver fluke *Fasciola hepatica* in sheep host bile and during in vitro culture ex host. *Mol. Cell. Proteom.* 6(6):963-972.
- Mulcahy G, Dalton JP (2001). Cathepsin L proteases as vaccines against infection with *Fasciola hepatica* (liver fluke) in ruminants. *Res. Vet. Sci.* 70:83-86.
- Mulcahy G, O'Connor F, McGonigle S, Dowd A, Clery DG, Andrews SJ, Dalton JP (1998). Correlation of specific antibody titre and avidity with protection in cattle immunized against *Fasciola hepatica*. *Vaccine* 16:932-939.
- Nour Eldin MS, EL-Ganaini GA, Abou EL-Enin AM, Hussein EM, Sultan DM (2004). Evaluation of seven assays detecting serum immunoglobulin classes and subclasses and salivary and faecal secretory IgG against *Fasciola* excretory-secretory (E/S) antigen in diagnosing Fascioliasis. *J. Egypt. Soc. Parasitol.* 34:691-704.
- Ozer BL, Ender SG, Yuksel G, Gurden YU, Sedat B (2003). Endoscopic extraction of living *Fasciola hepatica*: Case report and literature review. *Turk. J. Gastroenterol.* 14(1):74-77.
- Parkhouse RM, Almond NM, Cabrera Z, Harnett W (1987). Nematode antigens in protection, diagnosis and pathology. *Vet. Immunol. Immunopath.* 17:313-324.
- Perez-Ecija RA, Mendes RE, Zafra R, Buffoni L, Martinez-Moreno A, Perez J (2010). Pathological and parasitological protection in goats immunised with recombinant cathepsin L1 and challenged with *Fasciola hepatica*. *Vet. J.* 185(3):351-353.
- Piacenza L, Acosta D, Basmadjian I, Dalton JP, Carmona C (1999). Vaccination with cathepsin L proteinases and with leucine purified cysteine proteinases of *Fasciola hepatica* decreases worm fecundity. *Exp. Parasitol.* 78:132-148.
- Robinson MW, Alvarado R, To J, Hutchinson AT, Dowdell SN, Lund M, Turnbull L, Whitchurch CB, O'Brien BA, Dalton JP, Donnelly S (2012). A helminth cathelicidin-like protein suppresses antigen processing and presentation in macrophages via inhibition of lysosomal vATPase. *FASEB J.* 26(11):4614-4627.
- Robinson MW, Dalton JP (2009). Zoonotic helminth infections with

- particular emphasis on fasciolosis and other trematodiasis. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 364:2763-2776.
- Robinson MW, Corvo I, Jones PM, George AM, Padula MP, To J, Cancela M, Rinaldi, G, Tort JF, Roche L, Dalton JP (2011a). Collagenolytic activities of the major secreted cathepsin L peptidases involved in the virulence of the helminth pathogen *Fasciola hepatica*. *PLoS Negl. Trop. Dis.* 5(4):e1012.
- Robinson MW, Dalton JP, Donnelly S (2008a). Helminth pathogen cathepsin proteases: it's a family affair. *Trends Biochem. Sci.* 33(12):601-608.
- Robinson MW, Donnelly S, Hutchinson AT, To J, Taylor NL, Norton RS, Perugini MA, Dalton JP (2011b). A family of helminth molecules that modulate innate cell responses via molecular mimicry of host antimicrobial peptides. *PLoS Pathog.* 7(5):e1002042.
- Robinson MW, Tort JF, Lowther J, Donnelly SM, Wong E, Xu W, Stack CM, Padula M, Herbert B, Dalton JP (2008b). Proteomics and phylogenetic analysis of the cathepsin L protease family of the helminth pathogen *Fasciola hepatica*: expansion of a repertoire of virulence-associated factors. *Mol. Cell. Proteom.* 7(6):1111-1123.
- Rokni MB, Baghernejad A, Mohebbi M, Kia EB (2004). Enzyme linked immunotransfer blot analysis of somatic and excretory-secretory antigens of *Fasciola hepatica* in diagnosis of human Fascioliasis. *Iranian J. Pub. Health* 33:8-13.
- Ruiz Navarrete MA, Arriaga C, Bautista CR, Morilla A (1993). *Fasciola hepatica*: characterization of somatic and excretory-secretory antigens of adult flukes recognized by infected sheep. *Rev. latinoamer. Microbiol.* 35:301-307.
- Sanitago N, Hillyer GV, Garcia-Rosa M, Morale MH (1986). Identification of functional *Fasciola hepatica* antigens in experimental infection in rabbits. *Am. J. Trop. Med. Hyg.* 35(1):135-140.
- Smith AM, Dowd AJ, McGonigle S, Keegan PS, Brennan G, Trudgett A, Dalton JP (1993). Purification of a cathepsin L-like proteinase secreted by adult *Fasciola hepatica*. *Mol. Biochem. Parasitol.* 62(1):1-8.
- Smith SK, Pettit D, Newlands GF, Redmond DL, Skuce PJ, Knox DP, Smith WD (1999). Further immunization and biochemical studies with a protective antigen complex from the microvillar membrane of the intestine of *Haemonchus contortus*. *Parasit. Immunol.* 21:187-199.
- Smith WD, Smith SK, Pettit D (2000). Evaluation of immunization with gut membrane glycoproteins of *Ostertagia ostertagi* against homologous challenge in calves and against *Haemonchus contortus* in sheep. *Parasit. Immunol.* 22:239-247.
- Sobhon P, Anantavara S, Dangprasert T (1996). *Fasciola gigantica*: Identification of adult antigens, their tissue sources and possible origins. *J. Sci. Soc. Thai.* 22:143-162.
- Thivierge K, Cotton S, Schaefer DA, Riggs MW, To J, Lund ME, Robinson MW, Dalton JP, Donnelly SM (2013). Cathelicidin-like helminth defence molecules (HDMs): absence of cytotoxic, antimicrobial and anti-protozoan activities imply a specific adaptation to immune modulation. *PLoS Negl. Trop. Dis.* 7(7):e2307.
- Toet H, Piedrafita DM, Spithill TW (2014). Liver fluke vaccines in ruminants: strategies, progress and future opportunities. *Int. J. Parasitol.* 44(12):915-927.
- Viyanant V, Krailas D, Sobhon P (1997). Diagnosis of cattle fasciolosis by the detection of a circulating antigen using a monoclonal antibody. *Asian Pac. J. Allergy Immunol.* 15:153-159.
- Wedrychowicz H, Lamparska M, Kesik M, Kotowski G, Mieszczanek J, Jedlina-Panasuk L, Plucienniczak A (2003). The immune response of rats to vaccination with the cDNA or protein forms of the cysteine proteinase of *Fasciola hepatica*. *Vet. Immunol. Immunopathol.* 94:83-93.
- Wilson RA, Wright JM, de Castro-Borges W, Parker-Manuel SJ, Dowle AA, Ashton PD, Young ND, Gasser RB, Spithill TW (2011). Exploring the *Fasciola hepatica* tegument proteome. *Int. J. Parasitol.* 41(13-14):1347-1359.
- World Health Organization Headquarters (2006). Report of the WHO Informal Meeting on use of triclabendazole in fascioliasis control, Geneva, Switzerland.
- Zafra R, Perez-Ecija RA, Buffoni L, Moreno P, Bautista MJ, Martinez-Moreno A, Mulcahy G, Dalton JP, Perez J (2013a). Early and late peritoneal and hepatic changes in goats immunized with recombinant cathepsin L1 and infected with *Fasciola hepatica*. *J. Comp. Pathol.*, 148(4):373-384.
- Zafra R, Perez-Ecija RA, Buffoni L, Pacheco IL, Martinez-Moreno A, La Course EJ, Perally S, Brophy PM, Perez J (2013b). Early hepatic and peritoneal changes and immune response in goats vaccinated with a recombinant glutathione transferase sigma class and challenged with *Fasciola hepatica*. *Res. Vet. Sci.* 94(3):602-609.
- Zafra R, Buffoni L, Perez-Ecija RA, Mendes RE, Martinez-Moreno A, Martinez-Moreno FJ, Perez J (2009). Study of the local immune response to *Fasciola hepatica* in the liver and hepatic lymph nodes of goats immunised with a peptide of the Sm14 antigen. *Res. Vet. Sci.* 87(2):226-232.
- Zheng HJ, Tao Zheng-Hou CW, Pessens WF (1990). Comparison of dot-ELISA with sandwich ELISA for the detection of circulating antigens in patients with Bancroftian filariasis. *Am. J. Trop. Med. Hyg.* 42:546-549.



# International Journal for Biotechnology and Molecular Biology Research

*Related Journals Published by Academic Journals*

- *African Journal of Environmental Science & Technology*
- *Biotechnology & Molecular Biology Reviews*
- *African Journal of Biochemistry Research*
- *African Journal of Microbiology Research*
- *African Journal of Pure & Applied Chemistry*
- *Journal of Cell and Animal Biology*
- *African Journal of Biotechnology*
- *Scientific Research and Essays*

**academic**Journals